Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Bright Minds Biosciences Inc DRUG

Primary Symbol: C.DRUG

Healthcare Biotechnology

Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant... see more

Add To Watchlist

Recent & Breaking News (CSE:DRUG)

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

GlobeNewswire 3 days ago

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

GlobeNewswire November 4, 2024

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

GlobeNewswire October 21, 2024

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

GlobeNewswire October 18, 2024

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

GlobeNewswire October 16, 2024

Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA(TM) Technology

GlobeNewswire October 16, 2024

Bright Minds is Unaware of Any Material Changes

Newsfile October 15, 2024

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

GlobeNewswire October 3, 2024

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

GlobeNewswire September 19, 2024

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

PR Newswire September 12, 2024

Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management

Canada NewsWire December 6, 2023

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

GlobeNewswire August 8, 2023

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

GlobeNewswire July 20, 2023

Thinking about buying stock in Mind Medicine (MindMed), OPKO Health, Grange Resources, Hyzon Motors, or Bright Minds Biosciences?

PR Newswire July 14, 2023

CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)

Newsfile July 12, 2023

Bright Minds Announces Effective Date of Share Consolidation

GlobeNewswire July 11, 2023

Bright Minds Announces Proposed Share Consolidation

GlobeNewswire June 22, 2023

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

GlobeNewswire April 19, 2023

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

GlobeNewswire April 10, 2023

Bright Minds Biosciences (CSE:DRUG) continues to make headway in 2023

Brieanna McCutcheon February 27, 2023